Articles tagged with Ovarian Cancer
Researchers found that 68% of invasive low-grade ovarian tumors and 61% of precancerous lesions carried one of the three common mutations in BRAF or KRAS. Blocking KRAS-BRAF signaling may provide more effective therapy for these cancers, which generally do not respond well to conventional chemotherapy.
Researchers at Fox Chase Cancer Center developed a transgenic mouse model of epithelial ovarian cancer, allowing scientists to study the disease's progression from early stages. The model has the potential to facilitate advances in early detection and treatment of ovarian cancer.
Researchers at Vanderbilt University Medical Center found that COX-1, not COX-2, is expressed in epithelial ovarian cancer tissue samples. This discovery may lead to the development of new treatments for ovarian cancer by blocking both COX-1 and COX-2.
Two trials found that adjuvant chemotherapy improved recurrence-free survival by 8-11% and overall survival by 5-9%, primarily benefiting patients with unrecognized residual disease. These findings suggest that adjuvant chemotherapy may be most effective in patients with non-optimal surgical staging.
Researchers at Johns Hopkins Medicine conducted a study on combined PET-CT for detecting ovarian cancer, finding that the combination showed high sensitivity (73.6%) and specificity (100%) rates. This improved detection accuracy compared to using PET scans alone.
Researchers used digital SNP analysis to detect ovarian cancer in 87% of early-stage and 95% of late-stage patients, with high total DNA amounts found in most cancer cases. The test holds promise for improved detection in a wide range of cancers.
Two new studies published in the Journal of the National Cancer Institute identified key risk factors for classical Kaposi's sarcoma and found that smoking may decrease the risk of this disease. Meanwhile, research on leptin suggests it controls breast cancer cell proliferation. Additionally, a potential screening tool for ovarian canc...
A new study published in Obstetrics and Gynecology found that aspirin inhibited ovarian tumor cell growth by as much as 68 percent. Combining aspirin with a monoclonal antibody targeting the HER-2/neu protein resulted in an even greater suppression of growth, decreasing cancer cell growth by 84 percent.
Research studies found small but statistically significant increases in cancer risks among BRCA1 mutation carriers, including colon, liver, pancreatic, and cervical cancers. Additionally, male BRCA1 mutation carriers had a slightly elevated risk of prostate cancer.
Researchers at Memorial Sloan-Kettering Cancer Center have uncovered the function of the BRCA2 protein, which interacts directly with DNA to repair genetic damage. This new understanding sheds light on how mutations in the BRCA2 gene contribute to inherited breast and ovarian cancers.
A study by Nikola Pavletich and colleagues reveals that BRCA2 protein binds to damaged DNA, repairing it. This discovery sheds light on the mechanism of breast cancer development and opens new avenues for treatment strategies.
A review highlights the association between excess body weight and increased cancer risk, particularly in colon, breast, endometrium, oesophagus, and kidney. The study suggests that alterations in hormone metabolism may play a role in this link, emphasizing the importance of weight management for cancer prevention.
Research identifies young women with breast cancer at increased risk of ovarian cancer, including those with BRCA1 and BRCA2 gene mutations. The study suggests that these women may benefit from prophylactic oophorectomy or counseling.
A new study from the International Collaborative Ovarian Neoplasm (ICON) Collaborators found that paclitaxel plus carboplatin produces similar effectiveness to other treatments for women with ovarian cancer, but with more serious side effects. Carboplatin may be considered a preferred treatment option due to its better toxicity profile.
A study found that hereditary BRCA1 and BRCA2 ovarian cancers have similar gene expression profiles to sporadic ovarian cancers. The research suggests shared molecular mechanisms between hereditary and sporadic ovarian carcinogenesis exist.
Researchers found that women at high and elevated risk of ovarian cancer are less likely to get screened than those at lower risk. Most women overestimate their risk, with only 11% correctly estimating it.
Researchers discovered significantly higher plasma ANP and proANP-(1-30) levels in women with primary ovarian cancer compared to healthy controls. The study suggests that these peptides may play a role in the development of malignant ascites associated with ovarian cancer.
A new study has found that women with the highest levels of sex hormones are at roughly twice the risk of developing breast cancer compared to those with lower levels. Additionally, researchers have discovered a potential therapy for glioblastomas using a fusion protein that shows little toxicity. Reproductive hormones have also been l...
A new study found that hormone replacement therapy, particularly estrogen alone, may increase the risk of epithelial ovarian cancer in postmenopausal women with an intact uterus. Women who used sequential progestins with estrogens had a higher risk of developing ovarian cancer compared to those who never used HRT.
Researchers found that women who received predictive genetic testing for hereditary breast and ovarian cancer took practical measures, such as regular medical exams, rather than experiencing significant distress. About 10% opted for prophylactic mastectomy, while 37% had already undergone oophorectomy before testing.
A commonly prescribed medication for treating endometriosis appears to elevate the risk of ovarian cancer, according to a new study. Women taking danazol were nearly three times more likely to develop ovarian cancer than those taking leuprolide, an anti-androgenic medication.
Researchers found that thrombocytosis correlates with more aggressive ovarian cancer and poorer response to treatment. Patients with thrombocytosis had higher CA-125 levels, advanced stage disease, and greater tendency of cancer spread.
Research found that African-American women with ovarian cancer are at a 30% increased risk of death from any cause compared to Caucasian women. The study also revealed significant differences in tumor stage, lymph node involvement, and surgery rates between the two ethnic groups. Median survival times were also shorter for African-Amer...
A study at Memorial Sloan Kettering Cancer Center found that BRCA mutation carriers are more likely to be diagnosed with early-stage breast and ovarian cancers. The research showed that intensive screening and preventive surgery can lead to the detection of these cancers, but also highlights the limitations of screening.
A new computer-based algorithm identifies a distinct proteomic pattern that distinguishes malignant from benign tumours within the ovary with 100% sensitivity and 95% specificity. This technique may help screen for ovarian cancer in high-risk and general populations.
A study led by Joellen Schildkraut at Duke University Medical Center found that oral contraceptives with higher levels of progestin may be more protective against ovarian cancer than those with lower progestin potency. Higher progestin levels were associated with a significant reduction in risk, even for short periods of use.
Researchers have identified matrix metalloproteinases as a key player in the spread of prostate cancer to the bone, offering a new target for treatment. Additionally, a genetic marker may be useful in predicting survival rates for patients with diffuse large B-cell lymphoma, while oral contraceptive use has been found to reduce ovarian...
A new study analyzing oral contraceptive use among women with epithelial ovarian cancer found a significant association between progestin levels and reduced risk. Women using low-progestin/high-estrogen contraceptives were more likely to develop ovarian cancer compared to those using high-progestin/high-estrogen contraceptives.
Researchers found that Raloxifene stimulated the growth of ovarian cancer cell lines, raising concerns about its use in ER+ patients. The study advises caution when prescribing Raloxifene to women with a history of breast cancer and ovarian cancer.
Researchers found that raloxifene stimulates cell growth in ovarian adenocarcinoma cells with estrogen receptors, increasing the risk of recurrence. The study suggests caution for women with a history of breast cancer and estrogen receptor-positive ovarian cancer.
A new study reveals that the BRCA2 gene, linked to breast and ovarian cancers, plays a previously unsuspected role in human cell division. Inactivating the BRCA2 protein delays cells' progress through mitosis, suggesting a potential new target for cancer treatment.
A new platinum-based cancer drug, BBR3464, has shown promising activity against ovarian cancer that is resistant to cisplatin. The drug, developed by Nicholas Farrell and his team, has been found to be significantly more potent than cisplatin and may offer new hope for the treatment of this devastating disease.
Researchers found that women at high risk for breast and ovarian cancer scored very low on measures of psychological distress and disorders. Despite having a high-risk profile, these women had little or no worries about developing the disease.
Researchers at the University of Pittsburgh Medical Center found that low-dose oral contraceptives offer a 40% reduced risk of ovarian cancer, similar to high-dose pills. The protection begins soon after use and continues for at least 30 years after stopping.
Introgen presents Phase I trial results on RPR/INGN 201, showing safety and expression in ovarian cancer, lung carcinoma, and glioblastoma patients. The therapy has demonstrated significant potential in treating these life-threatening conditions.
The data from an ongoing Phase 1/2 trial of O-Vax in patients with advanced ovarian cancer indicates that the vaccine induces a positive immunological response, as measured by a delayed type hypersensitivity test. Favorable clinical responses were also observed, including complete regression of tumors and normalization of CA-125 levels.
The company presented Phase II data of tgDCC-E1A, a lead cancer therapy, which showed a 45% objective response rate in patients with recurrent head and neck squamous cell carcinoma. Preclinical studies also demonstrated the ability of E1A to sensitize tumors to radiation and chemotherapy.
Researchers have reported promising results from a Phase I-II trial of an ovarian cancer vaccine made from patient's own cancer cells. Eight of 10 patients showed immunological response, with one experiencing complete tumor disappearance and CA125 levels normalization.
Three Cedars-Sinai physicians are leading a fight against women's cancers through innovative research, clinical care, and genetic screenings. Beth Karlan focuses on curing and preventing ovarian cancer, while Maren Scheuner develops personalized prevention plans for breast, endometrial, and ovarian cancers.
A Northwestern University researcher is leading a five-year, $5 million National Cancer Institute-sponsored study to improve current methods and evaluate new tests for detecting early-stage ovarian cancer. The study aims to identify novel biomarkers that can detect ovarian cancer in its early stages.
Researchers at Fox Chase Cancer Center are conducting a clinical trial to investigate the efficacy of fenretinide, a vitamin A-related medicine, in preventing ovarian cancer. Women with high-risk factors for breast and ovarian cancer will take part in this study to examine the molecular effects of fenretinide on ovarian tissue.
Women at high risk for ovarian cancer experience depression when concerned about passing the disease to their daughters. A study found that 33% of participants were depressed during initial assessments and 38% during follow-ups, with concern for daughters being a leading source of distress.
The Pacific Ovarian Cancer Research Consortium aims to discover genes, develop a cancer vaccine, and improve treatment outcomes for ovarian cancer. The five-year study will involve researchers from several institutions and involve at least 3,500 women in its various studies.
A clinical trial at UNC is testing the effectiveness of LY353381, a selective estrogen receptor modulator (SERM), for treating ovarian and endometrial cancers. The drug has minimal side effects compared to traditional chemotherapy.
A study suggests that an imbalance in genes expressed on the X chromosome may lead to ovarian cancer development. The research found nonrandom X-chromosome inactivation in over 50% of women with invasive ovarian cancer, particularly those with BRCA1 mutations.
Researchers found that progestin activates apoptosis in the ovarian lining, preventing precancerous cells from becoming malignant. The study suggests that periodically administering progestin could be a highly effective preventive treatment for ovarian cancer.
A multi-center study provides clear guidelines for genetic testing in women with breast cancer, identifying those at high risk of ovarian cancer. The study found that nearly 40% of participants had abnormalities in BRCA1 and BRCA2 genes, associated with a 10-fold increase in ovarian cancer risk.
Researchers successfully delivered and expressed an E1A gene in both diseased and normal human cells using a proprietary non-viral liposomal delivery mechanism. The study showed decreased levels of surrogate tumor markers in three patients with breast and ovarian cancers, indicating potential as a treatment for various types of cancer.
Researchers at Thomas Jefferson University have created an autologous ovarian cancer vaccine that stimulates an immune response in patients, showing promise for treatment. The vaccine is custom-made for each patient and has been safe with no significant side effects, paving the way for further clinical trials.
Researchers found a strong link between increased ovulatory cycles and p53 genetic mutations in ovarian cancer. Women at high risk can protect themselves by reducing their ovulation through birth control, pregnancy, or breast-feeding.
A new study found that prophylactic surgery can prolong life expectancy by approximately 8.5 years, but at a significant impact on quality of life. The study also concluded that prophylactic surgery is cost-effective compared to cancer treatments.